Analysis of NK cell function in patients with multiple myeloma

Analysis of NK cell function in patients with multiple myeloma - MM-NK function

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022764

Enrollment

Registered

2016-06-16

Start date

2016-05-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed myeloma Patients (>=20 years old) with symptomatic myeloma defined by IMWG criteria 2. Relapse/Refractory myeloma Relapse or refractory (defined by IMWG) to induction, stem cell transplantation, consolidation and/or maintenance therapy. 3. Plateau phase of myeloma Patients who achieved plateau phase after treaments. 4. Healthy donor (>=20 years old) with written informed concent.

Exclusion criteria

Exclusion criteria: 1)Who does not agree with the participation into the study. 2)Who can not understant the explanation about this study. 3)Who should be excluded judged by principal investigator.

Design outcomes

Primary

Measure	Time frame
To analyze the quantitive and qualitative status in patients with multiple myeloma. 1)The number of NK cells 2)Surface proteins 3)Cytotoxic activities 4)Response to cytokines in NK cells	—

Secondary

Measure	Time frame
To evaluate the effect of monoclonal antibodies on NK cells. 1)Proliferation effects 2)Survival effects 3)Cytotoxic activities To evaluate the effect of NK cells on myeloma cells. 4)Cytotoxic activities of NK cells against myeloma cells 5)Effects of chemotherapy and stem cell transplantation on NK cells	—

Countries

Japan

Contacts

Public ContactShotaro Hagiwara

National Center for Global Health and Medicine Division of Hematology

shagiwar@hosp.ncgm.go.jp+81-3-3202-7181

Outcome results